At present, large numbers of at-risk women are treated in order to prevent relatively small numbers of breast cancers. There is a need to define risk more precisely in order to target interventions and a need to improve their efficacy. Risk estimations currently depend upon integration of familial and endocrine risk factors. We have demonstrated that the Tyrer--Cuzick model that takes both factors into account more fully is superior to other risk prediction models in our clinic \[[@B1]\]. However, prediction remains imprecise for the individual. Attempts are being made to take additional risk factors into account, including mammographic density \[[@B2]\], serum estradiol concentration and bone density. It seems probable that a better understanding of the interactions between stromal and epithelial cells in the breast including fibroblasts, adipocytes, macrophages and blood vessels will ultimately lead to better prediction. We have shown that 5% loss of body weight during mid life reduces postmenopausal breast cancer risk by 40% \[[@B3]\], and overviews indicate that use of NSAIDs \[[@B4]\] and exercise \[[@B5]\] may reduce risk by approximately 30%. The mechanisms of these risk reductions are not clear but gene array studies indicate that calorie restriction and exercise predominantly reduce the expression of genes related to inflammation \[[@B6],[@B7]\]. This raises the question of whether all these interventions act by similar mechanisms. A better understanding of the mechanisms of mammographic density and mammary cell senescence is required. Both are associated with fibroblasts that increase and stimulate proliferation of local epithelial cells \[[@B8],[@B9]\]. Since mammographic density is a major risk factor, its reversal is likely to be beneficial. Another stromal target is aromatase. All adjuvant aromatase inhibitor (AI) trials have shown an approximately 50% contralateral breast cancer reduction compared with tamoxifen \[[@B10]\]. Since tamoxifen reduces contralateral risk by about 50% compared with placebo, AIs may reduce risk by 70--80%. Trials to test this hypothesis are underway (IBIS II, MAP3). The aforementioned considerations indicate that the stroma and stroma--epithelial interactions are already targets for preventive measures, and this is likely to expand and lead to new interventions such as NF-κB inhibition \[[@B11]\] and SIRT1 activation \[[@B12]\].
